Posted in | News | Materials Processing

Clairvoyante Secures Series B Funding to Advance LCD Display Technology

Clairvoyante, Inc. a licensor of unique pixel architectures and algorithms that enhance the performance of Liquid Crystal Displays (LCD’s), today announced the closing of the Company’s Series B financing led by American River Ventures with participation from Intel Capital, Rocket Ventures and Yasuda Capital. Also participating in the round were existing investors, Selby Venture Partners, Pacifica Fund and The Angel’s Forum.

“Advanced display technology is essential to the next generation of mobile devices, notebook PCs and High Definition TV,” said John Kunhart, General Manager - American River Ventures. “The market is demanding cost-effective, high resolution screens that are brighter, yet consume less power. The Clairvoyante PenTile Matrix™ is a key technology for flat panel manufacturers to meet these market needs”, he added.

The Company provides optimized pixel layouts and subpixel rendering (SPR) algorithms for high performance display systems. The PenTile Matrix technology takes advantage of the processing characteristics of the human vision system to produce displays with higher brightness, higher resolution, lower power and cost efficiency.

Clairvoyante has engaged 10 of the world’s leading display manufacturers to develop enhanced products with the Company’s PenTile Matrix system. “This new round of funding will enable us to expand our Sales, Marketing and Technical Support capabilities as our customers move toward high volume production” said Dr. Garry Garrettson, CEO of Clairvoyante, Inc..

For more information on liquid crystal displays, click here.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.